Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2025, Vol. 57 ›› Issue (4): 644-649. doi: 10.19723/j.issn.1671-167X.2025.04.003

Previous Articles     Next Articles

Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus

Boda GUO1, Min LU2, Guoliang WANG1, Hongxian ZHANG1, Lei LIU1, Xiaofei HOU1, Lei ZHAO1, Xiaojun TIAN1, Shudong ZHANG1,*()   

  1. 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Pathology, Peking University Third Hospital, Peking University School of Basic Medical Sciences, Beijing, 100191, China
  • Received:2025-03-14 Online:2025-08-18 Published:2025-08-02
  • Contact: Shudong ZHANG
  • Supported by:
    the National Natural Science Foundation of China(82473287); the Beijing Natural Science Foundation(7232212)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To compare the clinicopathological characteristics and prognostic outcomes between patients with clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC) accompanied by venous tumor thrombus. Methods: A retrospective analysis was conducted on clinical and pathological data from patients with RCC and venous tumor thrombus treated in the Department of Urology at Peking University Third Hospital between January 2014 and February 2024. Patients were stratified into two groups based on pathological type: ccRCC and nccRCC. Comparisons of baseline characteristics, intraoperative situation, and prognosis between the two groups were performed using t-tests, Mann-Whitney U tests, chi-square tests, and Log-rank tests. Survival curves were generated using the Kaplan-Meier method. Results: A total of 437 patients were included, with a median age of 58 years, including 317 males and 120 females. The cohort comprised 366 cases of ccRCC and 71 cases of nccRCC. The non-clear cell group included 38 cases (53.5%) of papillary renal cell carcinoma, 2 cases (2.8%) of chromophobe renal cell carcinoma, 11 cases (15.5%) of unclassified renal cell carcinoma, 19 cases (26.8%) of molecularly defined renal cell carcinoma, and 1 case (1.4%) of collecting duct carcinoma. Compared with the clear cell renal carcinoma group, patients in the non-clear cell carcinoma group demonstrated a younger age at diagnosis (59 years vs. 55 years, P=0.010), larger tumor size (8.4 cm vs. 9.5 cm, P=0.025), higher rates of lymph node metastasis (56.8% vs. 70.6%, P=0.034), more advanced tumor thrombus (P < 0.001) and pathological grading (P=0.010), longer surgical duration (272 minutes vs. 289 minutes, P=0.023), and shorter overall survival (80 months vs. 35 months, P < 0.001). Multivariate Cox analysis indicated that histologic type, distant metastasis, tumor thrombus grading, and sarcomatoid/rhabdoid differentiation were prognostic factors in the renal cell carcinoma patients with venous tumor thrombus. No significant differences were observed between the two groups in terms of gender, body mass index, tumor laterality, distant metastasis, sarcomatoid or rhabdoid differentiation, American Society of Anesthesiologists (ASA) score, surgical approach, conversion to open surgery, blood loss, or transfusion of red blood cells and plasma. Conclusion: Compared with patients with clear cell renal carcinoma and venous tumor thrombus, those with non-clear cell carcinoma and venous tumor thrombus exhibit earlier onset, more aggressive disease progression, and poorer prognosis.

Key words: Renal cell carcinoma, Venous tumor thrombus, Retrospective, Prognosis

CLC Number: 

  • R737.11

Table 1

Baseline clinical and tumor characteristics of clear cell and non-clear cell renal cell carcinoma patients with venous tumor thrombus"

Variables Total ccRCC nccRCC P
Number of patients 437 (100.0) 366 (83.8) 71 (16.2)
Age/years 58 (14) 59 (8) 55 (18) 0.010
Gender 0.191
  Male 317 (72.5) 270 (73.8) 47 (66.2)
  Female 120 (27.5) 96 (26.2) 24 (33.8)
BMI/(kg/m2) 24.0 (4.7) 24.0 (5.0) 24.1 (4.1) 0.734
Tumor laterality 0.194
  Left 167 (38.2) 135 (36.9) 32 (45.1)
  Right 270 (61.8) 231 (63.1) 39 (54.9)
Histologic type
  Clear cell 366 (83.8) 366 (100) -
  Papillary 38 (8.7) - 38 (53.5)
  Chromophobe 2 (0.5) - 2 (2.8)
  Unclassified 11 (2.5) - 11 (15.5)
  Molecularly defined 19 (4.3) - 19 (26.8)
  Collecting duct 1 (0.2) - 1 (1.4)
Tumor diameter/cm 8.6 (3.8) 8.4 (3.9) 9.5 (4.1) 0.025
N 0.034
  N0 177 (40.5) 158 (43.2) 20 (29.4)
  N1 260 (59.5) 208 (56.8) 48 (70.6)
M 0.074
  M0 315 (72.1) 270 (73.8) 45 (63.4)
  M1 122 (27.9) 96 (26.2) 26 (37.6)
Tumor thrombus grading < 0.001
  0 112 (25.6) 97 (26.5) 15 (21.1)
  1 73 (16.7) 61 (16.7) 12 (16.9)
  2 182 (41.6) 154 (42.1) 28 (39.4)
  3 37 (8.5) 25 (6.8) 12 (16.9)
  4 33 (7.6) 29 (7.9) 4 (5.7)
Sarcomatoid/rhabdoid differentiation 0.118
  Absent 374 (85.6) 309 (84.4) 65 (91.5)
  Present 63 (14.4) 57 (15.6) 6 (8.5)
Pathologic grade 0.010
  1-2 157 (35.9) 141 (38.5) 16 (22.5)
  3-4 280 (64.1) 225 (61.5) 55 (77.5)
ASA grade 0.233
  1-2 367 (84.0%) 304 (83.1) 63 (88.7)
  3-4 70 (16.0) 62 (16.9) 8 (11.3)

Table 2

Intraoperative situation of clear cell and non-clear cell renal cell carcinoma patients with venous tumor thrombus"

Variables Total ccRCC nccRCC P
Number of patients 437 (100.0) 366 (83.8) 71 (16.2)
Radical nephrectomy approach 0.112
  Open 157 (35.9) 124 (33.9) 33 (46.5)
  Laparoscopic 181 (41.4) 158 (43.2) 23 (32.4)
  Robotic 99 (22.7) 84 (22.9) 15 (21.1)
Conversion to open surgery* 8 (2.9) 7 (2.9) 1 (2.6) >0.999
Duration of surgery/min 273 (171) 272 (164) 289 (170) 0.023
Estimated blood loss/mL 500 (900) 500 (900) 575 (857) 0.361
RBC transfusion/mL 400 (800) 400 (800) 0 (800) 0.316
Plasma transfusion/mL 0 (400) 0 (400) 0 (400) 0.591

Table 3

Prognosis-related Cox regression analysis in patients with renal cell carcinoma patients with venous tumor thrombus"

Variables Univariate analysis Multivariate analysis
HR (95%CI) P HR (95%CI) P
Age/years
   < 60
  ≥60 1.344 (0.981, 1.841) 0.066
Gender
  Male
  Female 0.931 (0.651, 1.332) 0.695
BMI/(kg/m2)
   < 24
  ≥24 0.626 (0.456, 0.859) 0.004 0.772 (0.553, 1.078) 0.128
Tumor laterality
  Left
  Right 0.921 (0.671, 1.264) 0.611
Histologic type
  Clear cell
  Non-clear cell 2.386 (1.670, 3.409) < 0.001 2.277 (1.561, 3.321) < 0.001
Tumor size/cm
   < 8.5
  ≥8.5 1.199 (0.879, 1.637) 0.252
N
  N0
  N1 1.270 (0.919, 1.756) 0.148
M
  M0
  M1 2.582 (1.882, 3.543) < 0.001 2.250 (1.609, 3.146) < 0.001
Tumor thrombus grading
  0
  1 1.102 (0.657, 1.848) 0.712 0.986 (0.584, 1.666) 0.958
  2 1.246 (0.818, 1.896) 0.306 1.275 (0.824, 1.975) 0.276
  3 2.082 (1.207, 3.589) 0.008 1.502 (0.816, 2.766) 0.192
  4 2.399 (1.367, 4.211) 0.002 2.208 (1.207, 4.040) 0.010
Sarcomatoid/rhabdoid differentiation
  Absent
  Present 2.168 (1.454, 3.235) < 0.001 2.309 (1.520, 3.509) < 0.001
Pathologic grade
  1-2
  3-4 1.931 (1.362, 2.738) < 0.001 1.432 (0.998, 2.056) 0.051
ASA grade
  1-2
  3-4 1.399 (0.939, 2.083) 0.098
Radical nephrectomy approach
  Open
  Laparoscopic 1.483 (1.067, 2.060) 0.019 0.872 (0.596, 1.276) 0.481
  Robotic 0.884 (0.512, 1.525) 0.657 0.614 (0.349, 1.081) 0.091

Figure 1

Kaplan-Meier survival curves for clear cell and non-clear cell renal cell carcinoma (ccRCC and nccRCC) patients with venous tumor thrombus compared with overall survival"

1
Han B , Zheng R , Zeng H , et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4 (1): 47- 53.
2
Faria-Costa G , Freitas R , Braga I , et al. Renal cell carcinoma with venous tumor thrombus: 15 years of experience in an oncology center[J]. J Clin Med, 2024, 13 (20): 6260.
3
Hao X , Peng H , Chao Z , et al. Development and validation of a comprehensive predictive model for surgical planning in patients with renal cell carcinoma and inferior vena cava tumor thrombus[J]. Eur J Surg Oncol, 2025, 51 (1): 109381.
4
Huang Z , Liu Z , Zhuo L , et al. Risk factors for renal insufficiency and survival implications after radical nephrectomy and thrombectomy in renal cell carcinoma with tumor thrombus: A systematic review[J]. BMC Urol, 2025, 25 (1): 20.
5
Quinn AE , Bell SD , Marrah AJ , et al. The current state of the diagnoses and treatments for clear cell renal cell carcinoma[J]. Cancers (Basel), 2024, 16 (23): 4034.
6
Liu Z , Ge L , Zhao X , et al. Clinicopathological features of papillary renal cell carcinoma with venous tumor thrombus: Case series from a large Chinese center[J]. Clin Med Insights Oncol, 2022, 16, 11795549221092217.
7
Tilki D , Nguyen HG , Dall'Era MA , et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus[J]. Eur Urol, 2014, 66 (3): 577- 583.
8
Rabinowitz MJ , Esfandiary T , Cheaib J , et al. Characterizing tumor thrombus arising from non-clear cell renal cell carcinoma[J]. Eur Urol Open Sci, 2022, 43, 28- 34.
9
Wagner B , Patard JJ , Méjean A , et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma[J]. Eur Urol, 2009, 55 (2): 452- 459.
10
薛子璇, 唐世英, 邱敏, 等. 青年肾肿瘤伴瘤栓的临床病理特征及预后分析[J]. 北京大学学报(医学版), 2023, 55 (5): 802- 811.

doi: 10.19723/j.issn.1671-167X.2023.05.005
11
Blute ML , Leibovich BC , Lohse CM , et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int, 2004, 94 (1): 33- 41.
12
Moch H , Amin MB , Berney DM , et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours[J]. Eur Urol, 2022, 82 (5): 458- 468.
13
Siegel RL , Giaquinto AN , Jemal A . Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74 (1): 12- 49.
14
Zhao X , Liu Z , Chen JY , et al. Influence of tumor thrombus morphology on the surgical complexity in renal cell carcinoma with inferior vena cava tumor thrombus: A single-center, large-sample study from China[J]. World J Urol, 2024, 42 (1): 454.
15
Kim KH , You D , Jeong IG , et al. Type Ⅱ papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus[J]. BJU Int, 2012, 110 (11 Pt B): E673- E678.
16
Stewart GD , Welsh SJ , Ursprung S , et al. A Phase Ⅱ study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)[J]. Br J Cancer, 2022, 127 (6): 1051- 1060.
17
Cost NG , Delacroix SJ , Sleeper JP , et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus[J]. Eur Urol, 2011, 59 (6): 912- 918.
[1] Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661.
[2] Zezhen ZHOU, Liyuan GE, Fan ZHANG, Shaohui DENG, Ye YAN, Hongxian ZHANG, Guoliang WANG, Lei LIU, Yi HUANG, Shudong ZHANG. A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 704-710.
[3] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
[4] Yaqing MAO, Zhen CHEN, Yao YU, Wenbo ZHANG, Yang LIU, Xin PENG. Impact of type 2 diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1089-1096.
[5] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[6] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[7] Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639.
[8] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[9] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[10] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[11] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[12] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[13] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[14] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[15] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd